Abstract: Methods and systems for operating a Heating, Ventilating and Air Conditioning (HVAC) system in accordance with one of a plurality of operating modes. The plurality of operating modes include one or more of a health mode, an energy savings mode and a balanced mode. In some cases, the operating modes include two or more energy saving modes. The currently operating mode is selected based on the current operating conditions of the building and the desired goals of the building operator. The goals can include, for example, reducing energy usage, reducing pathogen risks, increasing air quality and/or a combination of these goals. In some cases, the operating modes are autonomously controlled. In some cases, the operating modes are manually controlled.

Abstract: Methods and systems for remote configuration of a building control system into a BMS based system are disclosed herein. One remote management device allowing a remote user to connect a new or legacy system to a BMS network includes a processor and memory, the memory having executable instructions that execute to receive identification information that allow a user on a user device to access a remote management application, send instructions to the gateway device to initiate a discovery protocol at the gateway device to identify any network devices connected to the gateway device, receive data related to each identified network device from the gateway device and create a device profile for each identified network device, initiate a discovery of origination points protocol to discover all origination points for data that are relevant to a particular device of the identified network devices, and update the device profile for that particular device.

Abstract: Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.

Abstract: An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s).

Abstract: An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s).

Abstract: The present invention relates to a process for the preparation of esomeprazole magnesium containing R-isomer greater than about 0.1% by wt. In particular, the present invention relates to a process for the preparation of esomeprazole magnesium dihydrate containing R-isomer greater than about 0.1% by wt.

Abstract: A topical pharmaceutical composition comprising therapeutically effective amounts of vitamin D or vitamin D analogues, corticosteroid and a straight chain C6-C28 fatty alcohol.

Abstract: The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer.

Abstract: The present invention is directed to a novel rapidly dissolvable pharmaceutical composition comprising zolmitriptan or pharmaceutically acceptable salts or esters thereof and least one direct compression filler. The pharmaceutical compositions of the present invention can advantageously be prepared in a solid dosage form, e.g. a tablet, utilizing directly compressible ingredients.

Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration comprising micronized atovaquone particles and at least one drug, wherein about 90% of the atovaquone particles have a volume diameter between about 4 ?m to about 8 ?m; and having a uniform release profile after a storage for at least three months at 40° C. and 75% relative humidity.

Abstract: The present invention relates to the pharmaceutical composition comprising sumatriptan succinate and naproxen sodium, with a proviso that both the active components are in admixture with each other.

Abstract: The present invention provides pharmaceutical compositions, essentially comprising less than about 95% by weight of an aliphatic amine polymer. The present invention relates to pharmaceutical compositions comprising aliphatic amine polymers of sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride; and methods of preparing pharmaceutical compositions thereof.

Abstract: The present invention relates generally to formulations containing raloxifene or pharmaceutical salts thereof, as the active pharmaceutical ingredient and a process for preparing the same.

Abstract: The present invention generally relates to a stable pharmaceutical composition that does not have a film coating which contains simvastatin, ezetimibe or pharmaceutically-acceptable salts thereof, and ascorbic acid.

Abstract: Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.

Abstract: The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.

Abstract: The invention provides stable pharmaceutical compositions comprising ACE inhibitor(s) and other pharmaceutically active substances which are susceptible to degradation, as well as processes for the preparation thereof, and methods of treatment involving administration of such compositions.